The U.S. pharmaceutical industry has expressed concern that the practices and procedures in national healthcare programs, including New Zealand’s Pharmaceutical Management Agency
(PHARMAC), which maintains their formulary, put “innovative pharmaceutical products,” often
made in the United States, at a disadvantage.